A circRNA Neoantigen Vaccine Elicits Potent Antitumor Immunity and Synergizes with Checkpoint Blockade in Melanoma - PubMed
3 hours ago
- #melanoma treatment
- #neoantigen immunotherapy
- #circRNA vaccine
- circRNA-based vaccine encoding melanoma neoantigens (circRNAMNA) suppresses tumor growth in mouse models and induces strong anti-tumor immunity.
- Single-cell RNA sequencing reveals that vaccination nearly eliminates the Ccl6+Mel tumor subcluster and increases antitumor monocytes/macrophages like Mono-Vcan and M1-like macrophages.
- The vaccine enhances T cell responses, increasing TCR diversity in CD4+ and CD8+ T cells, and synergizes with anti-TIGIT/PD1 checkpoint blockade for improved melanoma therapy.